

Mozambique Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

4 0 - 4								
1. Countr	Country: Mozambique							
2. Grant r	Grant number: 1819-MOZ-04c-X; 08-MOZ-08b-Y							
3. Date of	B. Date of Decision Letter: 21 December 2017							
4. Date of the Partnership Framework Agreement: 06 December 2013								
5. Progra	Programme title: New Vaccine Support (NVS), Pentavalent Routine							
6. Vaccin	Vaccine type: Pentavalent							
 Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID 								
8. Progra	Programme duration ¹ : 2009 - 2019							
 Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement) 								
	2009-2017	2018		2019	Total ²			
Programme Budget (US\$)	US\$44,703,048 ³	US\$1,712,500	US	\$\$1,952,000	US\$48,367,548			
10. Vaccine introduction grant (in US\$): Vaccine introduction grant of US\$288,500 disbursed on 28 October 2008								
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework								
Agreement) ⁴								
Type of supplies to be purchased		2009-2017			2018			
with Gavi funds in each year								
Number of Pen				2,204,000				
doses								
Annual Amounts (US\$)		US\$44,703,048 ⁵		US\$1,712,500				
12. Procurement agency: UNICEF. The Country shall release its co-financing								
payments each year to UNICEF.								
13. Self-procurement: Not applicable								

2 Chemin des Mines 1202 Geneva. Switzerland Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



14. Co-financing obligations: Reference code: 1819-MOZ-04c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

that will be presented with each failed in the relevant year.						
Type of supplies to be	2018	2019				
purchased with Country funds						
in each year						
Number of vaccine doses	764,500	1,090,000				
Value of vaccine doses (US\$)	US\$573,177					
Total co-financing payments	US\$594,000	US\$770,500				
(US\$) (including freight)						

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions:

The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard

Signed by,

On behalf of Gavi

What I hail

Hind Khatib-Othman Managing Director, Country Programmes 21 December 2017